

117TH CONGRESS  
2D SESSION

# H. RES. 1285

Requesting the President to transmit certain information to the House of Representatives relating to a waiver of intellectual property commitments under the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights.

---

## IN THE HOUSE OF REPRESENTATIVES

JULY 26, 2022

Mr. SMITH of Nebraska (for himself and Mr. BRADY) submitted the following resolution; which was referred to the Committee on Ways and Means

---

## RESOLUTION

Requesting the President to transmit certain information to the House of Representatives relating to a waiver of intellectual property commitments under the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights.

1       *Resolved*, That the President is requested to transmit  
2 to the House of Representatives, not later than 14 days  
3 after the date of the adoption of this resolution, copies  
4 of all documents, memoranda, advisory legal opinions,  
5 notes from meetings, audio recordings, records (including  
6 telephone and electronic mail records), correspondence, or  
7 other communications, or any portion of any such commu-

1 nications, to the extent that any such one or more items  
2 are within the possession of the President, that dem-  
3 onstrate—

4 (1) the waiver of intellectual property commit-  
5 ments under the World Trade Organization Agree-  
6 ment on Trade-Related Aspects of Intellectual Prop-  
7 erty Rights (in this resolution referred to as  
8 “TRIPS waiver”) that was agreed to on June 17,  
9 2022, will increase global supply and delivery of  
10 COVID–19 vaccines;

11 (2) the extent to which COVID–19 vaccines  
12 have been destroyed due to their expiration and the  
13 period during which this occurred;

14 (3) the proposed expansion of the TRIPS waiv-  
15 er to cover intellectual property related to  
16 diagnostics and therapeutics (in this resolution re-  
17 ferred to as the “proposed TRIPS waiver expan-  
18 sion”) will increase global supply and delivery of  
19 COVID–19 diagnostics or therapeutics;

20 (4) the TRIPS waiver or the proposed TRIPS  
21 waiver expansion will accelerate the end of the  
22 COVID–19 pandemic; and

23 (5) the People’s Republic of China will not ob-  
24 tain access to patents or other intellectual property  
25 related to COVID–19 vaccines, diagnostics, or thera-

- 1        peutics, even if China is expressly excluded from the
- 2        TRIPS waiver or the proposed TRIPS waiver expan-
- 3        sion.

